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FOR THE TODAY STUDY GROUP
OBJECTIVE — To determine the frequency of islet cell autoimmunity in youth clinically
diagnosed with type 2 diabetes and describe associated clinical and laboratory ﬁndings.
RESEARCHDESIGNANDMETHODS — Children(10–17years)diagnosedwithtype
2 diabetes were screened for participation in the Treatment Options for Type 2 Diabetes in
Adolescents and Youth (TODAY) study. Measurements included GAD-65 and insulinoma-
associated protein 2 autoantibodies using the new National Institute of Diabetes and Digestive
andKidneyDiseases/NationalInstitutesofHealth(NIDDK/NIH)standardizedassays,aphysical
examination, and fasting lipid, C-peptide, and A1C determinations.
RESULTS — Ofthe1,206subjectsscreenedandconsideredclinicallytohavetype2diabetes,
118 (9.8%) were antibody positive; of these, 71 (5.9%) were positive for a single antibody, and
47 were positive (3.9%) for both antibodies. Diabetes autoantibody (DAA) positivity was signif-
icantlyassociatedwithrace(P0.0001),withpositivesubjectsmorelikelytobewhite(40.7vs.
19%)(P0.0001)andmale(51.7vs.35.7%)(P0.0007).BMI,BMIzscore,C-peptide,A1C,
triglycerides, HDL cholesterol, and blood pressure were signiﬁcantly different by antibody
status. The antibody-positive subjects were less likely to display characteristics clinically asso-
ciated with type 2 diabetes and a metabolic syndrome phenotype, although the range for BMI z
score,bloodpressure,fastingC-peptide,andserumlipidsoverlappedbetweenantibody-positive
and antibody-negative subjects.
CONCLUSIONS — Obese youth with a clinical diagnosis of type 2 diabetes may have
evidenceofisletautoimmunitycontributingtoinsulindeﬁciency.Asagroup,patientswithDAA
have clinical characteristics signiﬁcantly different from those without DAA. However, without
islet autoantibody analysis, these characteristics cannot reliably distinguish between obese
young individuals with type 2 diabetes and those with autoimmune diabetes.
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T
ype 2 diabetes in youth was rarely
reported before the 1990s, but in-
creased in the late 1990s, associated
with the burgeoning of childhood obesity
(1–3). Type 2 diabetes now accounts for
15–87% of new-onset diabetes in U.S.
youth aged 10–20 years, varying with
race/ethnicity (4). In addition, there have
been signiﬁcant increases in the occur-
renceoftype1diabetesinthelast25years
(5–7). Given the obesity epidemic, many
youthwithtype1diabetesareeitherover-
weight or obese at diagnosis (8,9), mak-
ing it difﬁcult for clinicians to distinguish
between type 1 and type 2 diabetes based
on weight alone. As the classic criteria for
distinguishing between these two major
types of diabetes (i.e., age at onset and
weight) are increasingly blurred, there
has been a need to develop better meth-
ods of diabetes classiﬁcation in youth.
This dilemma was highlighted by the
SEARCH for Diabetes in Youth study,
which reported that 21.2% of children
aged 10–19 years of age with physician-
identiﬁed type 2 diabetes were found to
bepositiveforGAD-65antibodies(4).Al-
though the signiﬁcance of these antibod-
ies in children with phenotypic type 2
diabetes is not currently understood, in
adults in the UK Prospective Diabetes
Study (UKPDS) who had positive
GAD-65 antibodies and physician-
diagnosed type 2 diabetes, oral treatment
failed signiﬁcantly more rapidly than in
those without autoimmunity (94 vs. 14%
at 6 years) (10). These and other studies
suggest that there are clinically signiﬁcant
differencesbetweenindividualswithclin-
ical signs of type 2 diabetes and islet au-
toimmunity compared with those
without evidence of autoimmunity.
With the dramatic increase in type 2
diabetes in youth of all ethnic origins, the
importance of determining the effective-
ness of treatment options became a child
health priority. The Treatment Options
for Type 2 Diabetes in Adolescents and
Youth (TODAY) study is a National Insti-
tutes of Health (NIH)-sponsored multi-
center clinical trial designed to compare
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formin with rosiglitazone, and metformin
with an intensive lifestyle intervention
program in children 10–17 years of age
(11). In designing the TODAY study, the
UKPDS experience led to a decision to
exclude islet antibody-positive individu-
als from the trial. This report examines
islet autoimmunity in youth who were
considered by pediatric endocrinologists
to have type 2 diabetes based on their
phenotypic presentation. Subjects were
assessed for islet autoimmunity at the
screening visit for the TODAY study;
those with islet autoimmunity were ex-
cluded from participation. Clinical and
laboratory differences between islet anti-
body-positive and antibody-negative par-
ticipants at screening are described.
RESEARCH DESIGN AND
METHODS— The TODAY Study
Group is composed of 15 clinical centers,
a coordinating center, the National Insti-
tuteofDiabetesandDigestiveandKidney
Diseases(NIDDK)projectofﬁce,andcen-
tral cores and laboratories (a list of the
TODAY study centers and contributing
investigators at each center and of indus-
tries supporting the TODAY trial is found
in an online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0373/DC1). The protocol was ap-
proved by an External Evaluation Com-
mittee convened by NIDDK and by the
institutional review board of each partic-
ipatingcenter.ADataandSafetyMonitor-
ing Board convened by NIDDK reviews
progress and safety regularly throughout
the study. The TODAY study rationale,
design,andmethodshavebeendescribed
previously (11). All participants provided
informed consent, and minor children
conﬁrmed assent according to local
guidelines before participation in the
screening visit.
Screening visits (n  1,211) were
conducted from May 2004 to September
2008. The current article reports the re-
sults of the 1,206 subjects who had auto-
antibody determinations. Only patients
with fasting C-peptide levels 0.6 ng/ml
and negative IA-2 and GAD-65 autoanti-
bodies were eligible for participation in
the TODAY study.
Eligibility criteria included age
10–17years,diagnosisofdiabetesconsis-
tent with type 2 diabetes by standard cri-
teria (12) with duration 2 years, and
BMI 85th percentile at the visit or at
diagnosis. Exclusion criteria included di-
abetic ketoacidosis at any time after diag-
nosis, except for a single episode related
to a signiﬁcant intercurrent medical ill-
ness. Eligible subjects were screened
while using their current diabetes treat-
ment, and rapid-acting insulin was held
untilaftertheassessment.Theassessment
included height, weight, calculation of
BMI,andpresenceofacanthosisnigricans
by inspection. Blood pressure was mea-
sured using an automated device (CAS
Medical Systems) and appropriately sized
cuffandcheckedthreetimesafterthepar-
ticipant rested in the seated position for 5
min. Race/ethnicity was determined by
self-report using the 2000 Census collec-
tion format. A family history of diabetes
and additional demographic data were
obtained. Laboratory studies were per-
formed in the fasted state and included a
lipid proﬁle (total, LDL, and HDL choles-
terol and triglycerides), C-peptide, insu-
linoma-associated protein 2 (IA-2) and
GAD-65 autoantibodies, and A1C.
Laboratory methods
Samples were processed following stan-
dardized procedures and shipped on dry
ice to the Northwest Lipid Metabolism
and Diabetes Research Laboratories, Uni-
versity of Washington (Seattle, WA). C-
peptide was measured by a two-site
immunoenzymatic assay on a dedicated
instrument (Tosoh Bioscience, San Fran-
cisco, CA). The assay sensitivity is 0.05
ng/ml. A1C levels were determined by an
automated nonporous ion-exchange
high-performance liquid chromatogra-
phy system (G7; Tosoh Bioscience).
Measurements of total cholesterol,
triglycerides, and HDL cholesterol were
performed enzymatically using a Roche
reagent on a Roche Pmodule autoana-
lyzer. LDL cholesterol levels were calcu-
lated by the Friedewald equation for
samples with triglycerides 400 mg/dl
and by the Lipid Research Clinic Beta
Quantiﬁcation approach for those with
triglycerides 400 mg/dl.
Islet cell autoantibody assays for IA-2
and GAD-65 were initially performed at
the TODAY central laboratory. They were
subsequently conﬁrmed at the Diabetes
Research Institute Munich Laboratory
(Munich, Germany) using the new,
NIDDK standardized assay with stan-
dardized
35S-labeled GAD-65 or IA2-IC
proteins, according to the harmonized
NIDDK/NIH autoantibody methods. The
assays were calibrated using a set of stan-
dards with predetermined levels of
GAD-65 or IA-2 antibodies expressed in
arbitrary NIDDK units (DK units per ml).
The GAD-65 assay is 76% sensitive and
97% speciﬁc, and the IA-2 assay is 64%
sensitive and 99% speciﬁc. In the Diabe-
tesResearchInstituteMunichLaboratory,
a GAD-65–positive value is 43 DK
units/ml;anIA-2–positivevalueis5DK
units/ml.
Statistical methods
Data reported in this article primarily in-
clude descriptive statistics of the partici-
pants at the time of screening. When
appropriate, data are reported as median
with percentiles, mean  SD, or percent-
age within a category. Comparisons by
antibody status were made by ANOVA in
the case of normally distributed continu-
ous variables, the Kruskal-Wallis test for
nonnormallydistributedcontinuousvari-
ables, and the 
2 test for categorical vari-
ables. No adjustment was made for
multiple comparisons.
RESULTS— Participants (n  1,206)
had a median time from diabetes diagno-
sis to screening of 2.0 months (25th per-
centile 1, 75th percentile 6.3) and a
median age of 14.0 (12,13) years. More
than half were female (62.8%) and the
majority were from racial and ethnic mi-
nority groups (21.1% white, 34.0% His-
panic, 35.2% black, and 5.3% American
Indian). GAD-65 and IA-2 antibody titers
are shown in Fig. 1; 118 (9.8%) were an-
tibody positive, with 71 (5.9%) of these
positive for a single antibody and 47
(3.9%) positive for both GAD-65 and
IA-2 antibodies. Of the 71 with a single
antibody, 29 were positive for only
GAD-65 and 42 were positive for only
IA-2 (Fig. 1A and B).
Demographic characteristics are
shown in Table 1 according to diabetes
autoantibody (DAA) status. Distributions
of race/ethnicity and sex were signiﬁ-
cantly different (P  0.0001 and P 
0.0007, respectively). The antibody-
positive participants were more likely to
be white (40.7%) and male (51.7%) than
the antibody-negative subjects (19%
white; 35.7% male). Those with positive
DAA status were less likely to have a fam-
ily history of diabetes in a ﬁrst-degree rel-
ative than the antibody-negative
participants (31.4 and 53.2%, respec-
tively; P  0.0001). Almost 1 in 5
(18.8%) of the white subjects were anti-
body positive compared with less than 1
in 10 of the screened black (6.8%), His-
panic (8%), or American Indian subjects
(7.8%).
The clinical and laboratory ﬁndings
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body status. Both antibody-negative and
-positive groups were overweight or
obese, as required for screening eligibil-
ity; however, the median BMI and BMI z
scoreweresigniﬁcantlylowerintheDAA-
positive group (P  0.0001). Overall, the
antibody-positivesubjectswerelesslikely
to display clinical characteristics usually
associated with type 2 diabetes and the
metabolic syndrome phenotype, includ-
ing elevations in blood pressure and tri-
glycerides, low HDL cholesterol, and the
presence of acanthosis nigricans. Insulin
use was signiﬁcantly greater in the DAA-
positive group than in the DAA-negative
group (54.2 vs. 38.8%, respectively; P 
0.0013). Similarly, the DAA-positive
grouphadalowermedianC-peptidelevel
than the DAA-negative group (2.0 com-
pared with 3.8 ng/ml, respectively; P 
0.0001). Importantly, the antibody-
negative participants had 7.31 (95% CI
4.62–11.57) times the odds of having a
fasting C-peptide value above the upper
limit of normal (3 ng/ml) compared
with antibody-positive participants;
when adjusted for BMI z score, the odds
ratio remains signiﬁcant at 5.11 (95% CI
3.13–8.34). All differences between anti-
body-positive and -negative subjects re-
mained signiﬁcant when analyzed by
number of positive antibodies.
Figure 2 shows the distributions of
BMIzscoresandC-peptidelevelsaccord-
ing to antibody status. Figure 2A demon-
strates that there is almost complete
overlap of BMI z scores among the anti-
body-negative, single antibody–positive,
and double antibody–positive partici-
pants, although mean and median BMI z
scores were signiﬁcantly lower in the
DAA-positive groups. Although the C-
peptide values of the DAA-positive
groups are included within the range of
the values for the DAA-negative group,
the distributions of C-peptide levels are
signiﬁcantly different for DAA-positive
and -negative subjects, with many of the
DAA-negative subjects having C-peptide
values greater than the highest values
found in the DAA-positive groups.
CONCLUSIONS — Using the new
NIH standardized assay, 9.8% (118 of
1,206) of youth with BMI 85th percen-
tile and thought by pediatric endocrinol-
ogists to have type 2 diabetes were
positiveforGAD-65and/orIA-2antibod-
ies. Additional antibody-positive individ-
uals may have been identiﬁed had insulin
autoantibodiesorzinctransporter8auto-
antibodiesbeenmeasured.Previousinsu-
lin use or unclear history of insulin use in
the majority of subjects prevented the de-
termination of insulin autoantibodies,
and zinc transporter 8 antibody analysis
was not available at the outset of the
TODAY study (14).
Theantibody-positivegroupissignif-
icantly different from the antibody-
negative group, with fewer clinical and
laboratory ﬁndings characteristic of type
2 diabetes and more ﬁndings similar to
thosefoundintype1diabetes,i.e.,amore
equal male-to-female ratio, more likely to
be white, higher HDL cholesterol, and
lower triglycerides, C-peptide, and BMI z
scores (even though participation was
limited to overweight or obese individu-
Figure 1—Fasting C-peptide vs. antibody titer. Antibody levels are represented in NIDDK/NIH standardized DK units, and C-peptide values are
measured as nanograms per milliliter. A: GAD-65 antibody titers vs. fasting C-peptide. ‚, GAD-65 values for IA-2–negative subjects; , GAD-65
values for IA-2–positive subjects. GAD-65 values 45 DK units/ml are positive. B: IA-2 antibody titers vs. fasting C-peptide. ‚, IA-2 values for
GAD-65–negative subjects; , IA-2 values for GAD-65–positive subjects. IA-2 values 5.0 DK units/ml are positive. The normal range for fasting
C-peptide is 0.5–3.0 ng/ml.
Table 1—Demographic ﬁndings in antibody-negative and antibody-positive groups
n Antibody-negative n Antibody-positive P value
n 1,088 118
Age (years) 1,088 14 (12, 15) 118 13 (12, 15) NS
Duration of diabetes
(months) 1,045 1.9 (0.7, 6.1) 113 2.5 (0.7, 7.3) NS
Race/ethnicity (%) 1,088 118
White 19.0 40.7
Black 36.3 24.6
Hispanic 34.7 28.0
Asian 2.2 0.8
American Indian 5.4 4.2
Other 2.3 1.7
Female sex (%) 1,088 64.3 118 48.3 0.0007
Parent or full sibling
has diabetes (%) 875 53.2 93 31.4 0.0001
Data are % or median (25th, 75th percentile). NS, not signiﬁcant.
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guish phenotypically between individual
participants with positive GAD-65 or
IA-2 antibodies and those without anti-
bodies. Although the median BMI and C-
peptide values are signiﬁcantly different
between these two groups, the ranges of
both BMI z scores and C-peptide levels in
the antibody-positive subjects fall within
the range of those of the antibody-
negativeindividuals.Similarresultsapply
to lipid and blood pressure levels.
The ﬁnding of islet cell antibody-
positive adolescent patients in partici-
pants screened in the TODAY study is
consistent with other reports (13,15). In
SEARCH, 21.2% of children 10–19 years
ofagewithphysician-identiﬁedtype2di-
abetes were found to be positive for
GAD-65antibodies(4).Thehigherrateof
diabetes autoimmunity identiﬁed in
youth with “type 2 diabetes” in SEARCH
may be due to a higher background non-
Hispanic white population. In addition,
in the SEARCH report, the method used
for determining DAA was not the NIDDK
standardized assay, which makes it difﬁ-
cult to directly compare the results. Re-
cently, all SEARCH samples were
reanalyzed with the standardized assay;
when these data are published, it will be
interesting to compare our results to the
SEARCH data.
Whether these autoantibody-positive
individualshavebothautoimmunetype1
diabetes and insulin-resistant type 2 dia-
betes or more typical type 1 diabetes pre-
senting in overweight or have insulin
resistance due to their obesity is unclear
and controversial (16,17). The GAD-65
antibody–positive type 2 diabetes group
in SEARCH had a mean fasting C-peptide
level of 2.83  1.8 ng/ml (measured in
the same laboratory used in the TODAY
study), which is modestly higher than the
mean found in our subjects (2.30  1.62
ng/ml) but lower than that of the anti-
body-negative participants in both the
TODAY study (4.13  2.22 ng/ml) and
SEARCH (3.71  2.2 ng/ml). However,
the C-peptide in screened TODAY sub-
jects reported here was substantially
higherthanthatfoundinindividualswith
physician-diagnosed type 1 diabetes in
SEARCH (fasting C-peptide 0.75  0.6
ng/ml), suggesting more insulin resis-
tance in obese youth with a type 2 diabe-
tes phenotype with less insulin deﬁciency
compared with a more typical normal-
weight adolescent with type 1 diabetes.
A recent report compared insulin re-
sistance in youth with clinically diag-
nosed type 2 diabetes and positive DAA,
youth with type 2 diabetes and negative
DAA, and obese youth with normal glu-
cose tolerance (17). These authors re-
ported that insulin sensitivity was
signiﬁcantly impaired in DAA-negative
type 2 diabetic youth compared with
youth with islet autoimmunity and obese
controlyouth.However,therewasnodif-
ference in insulin sensitivity between the
latter two groups, suggesting that the de-
gree of insulin resistance in DAA-positive
youth is more typical of obesity than that
of type 2 diabetic youth, in whom an in-
herent genetic/epigenetic factor is be-
lieved to play a role. Because the youth
with autoimmunity do not have the same
degree of insulin resistance as that found
in those with DAA-negative type 2 diabe-
tes, the progression to diabetes must arise
inpartfromagreatercomponentof-cell
failure compared with that in the DAA-
negativetype2diabeticyouth,possiblyas
a result of islet autoimmunity. Indeed,
these authors demonstrated that insulin
secretion during a hyperglycemic clamp
was signiﬁcantly lower in phenotypic
type 2 diabetic youth with positive DAA
than in youth with negative DAA (17).
The biochemical proﬁle of our anti-
body-positive group is consistent with
these ﬁndings and those reported in adult
subjects enrolled in A Diabetes Outcome
Progression Trial (ADOPT), a treatment
trial in physician-diagnosed type 2 diabe-
tes. In this trial, subjects with positive
GAD-65 antibodies had lower fasting in-
sulin, signiﬁcantly lower homeostasis
model assessment of insulin resistance
and triglycerides and higher HDL choles-
terol than in those without GAD-65 auto-
antibodies, suggesting less insulin
resistance in the DAA-positive subjects
(18). The GAD-65–positive and –negative
groups did not differ overall with respect
to age, sex, BMI, waist circumference,
fasting glucose, or A1C levels. These re-
sults indicate that adolescent and adult
patients with “antibody-positive type 2
diabetes” have a similar clinical and met-
abolic phenotype, suggesting a similar
etiopathology. Thus, taken together with
our data, these results indicate that obese
individuals with diabetes and autoimmu-
nity are closer physiologically to their
normal-weight peers with type 1 diabetes
than to antibody-negative individuals
with type 2 diabetes.
Table 2—Physical, clinical, and fasting laboratory ﬁndings by diabetes antibody status at the screening assessment
n Antibody-negative n Antibody-positive P value
n 1,088 118
BMI 1,082 34.9 (30.3, 39.9) 115 29.1 (25.4, 35.2) 0.0001
BMI z score 1,082 2.3 (2.1, 2.6) 115 1.9 (1.5, 2.4) 0.0001
Systolic blood pressure 1,075 115.0 (107.7, 123.3) 114 110.5 (103.7, 115.7) 0.0001
Diastolic blood pressure 1,075 68.3 (63.3, 74.3) 114 64.7 (60.3, 70.0) 0.0001
Acanthosis nigricans (%) 1,032 84.4 108 67.8 0.0001
Insulin use (%) 1,088 38.8 118 54.2 0.0013
Metformin use (%) 1,088 73.8 117 62.7 0.0155
A1C (normal  3.9–6.1%) 1,082 6.9 (6.0, 8.8) 117 7.6 (6.2, 10.1) 0.0111
Fasting C-peptide (normal 
0.5–3.0 ng/ml) 1,088 3.8 (2.6, 5.2) 118 2.0 (1.2, 2.7) 0.0001
Total cholesterol 1,086 156 (135, 179) 118 151 (133, 173) 0.1156
LDL cholesterol 1,085 92 (74, 111) 117 87 (74, 101) 0.1351
HDL cholesterol 1,085 39 (33, 46) 117 43 (37, 51) 0.0001
Triglycerides 1,086 106.5 (73, 156) 118 77 (56, 120) 0.0001
Data are % or median (25th, 75th percentile).
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outcomes in type 2 diabetic individuals
who are DAA-positive. The UKPDS trial
reportedthatinyoungGAD-positivesub-
jects with physician-diagnosed type 2 di-
abetes oral treatment failed more rapidly
than in those without autoimmunity;
94% required insulin by the end of the
study, compared with 14% of antibody-
negative subjects. The mean time to insu-
lin requirement was 3 years in the
antibody-positive group (10). A smaller
report of adolescents initially diagnosed
with type 2 diabetes but later determined
to have markers predictive of risk for type
1 diabetes indicated that these youth re-
quired insulin therapy within 4 years
(19).
Ourresults,combinedwiththeabove
data, emphasize the importance of deter-
mining islet autoantibodies in all youth
and young adults thought to have type 2
diabetes. Young people with clinically di-
agnosed type 2 diabetes and unrecog-
nized islet autoimmunity may develop
metabolic decompensation with rapid
onsetofarequirementforinsulin.Knowl-
edge of the presence of autoimmunity in
overweight and obese young people with
diabetes can direct decisions regarding
initiation of insulin therapy to avoid this
preventable morbidity. In addition, all
youngpeoplewithtype2diabetesshould
be instructed about the signs and symp-
toms of severe insulin deﬁciency and the
importanceofseekingpromptmedicalat-
tention. Finally, obese youth with dia-
betes being considered for inclusion in
treatment trials and studies evaluating
outcomes of type 2 diabetes should
have determination of islet autoimmu-
nity, as the clinical course and out-
comes for those with DAA may be
signiﬁcantly different.
The strengths of this study were the
large sample size, the racial/ethnic diver-
sity, and the use of the new NIDDK/NIH
standardized islet cell antibody assay.
This study was limited to those with a
diagnosis of obesity-associated type 2 di-
abetes (BMI 85th percentile for age and
sex),soourﬁndingsmaynotgeneralizeto
all youth diagnosed clinically with type 2
diabetes.
Future studies of antibody-positive
adolescents and young adults with clini-
cal features of type 2 diabetes are needed
to determine their clinical course and op-
timal treatment regimens. It will be im-
portant to determine whether early
insulin therapy or other treatment ap-
proaches will be effective in preserving
residual -cell function in these youth.
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